Meeting
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
Authors
Zeynep Eroglu
Moffitt Cancer Center and Research Institute, Tampa, FL
Zeynep Eroglu , James Moon , Yana G. Najjar , Rupesh Kotecha , Vadim Spektor , Michael Wu , Elad Sharon , Kenneth F. Grossmann , Jedd D. Wolchok , Sapna Pradyuman Patel , Hussein A. Tawbi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT# 04511013
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9603)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9603
Abstract #
TPS9603
Poster Bd #
360b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee
Poster
2018 ASCO Annual Meeting
A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM).
First Author: Gustavo Schvartsman
Poster
2016 ASCO Annual Meeting
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
First Author: Yousef Zakharia
Poster
2015 ASCO Annual Meeting
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.
First Author: Kim Allyson Margolin